Bill Gates’ is about to mint millionaires (again) with Stargate.

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Christopher Twomey Biography and Net Worth

Director of Tandem Diabetes Care

Mr. Twomey has served on our board of directors since July 2013. Mr. Twomey has served as a director and chair of the audit committee of Bionano Genomics (Nasdaq: BNGO), a life sciences genome analysis instrumentation company since July 2018. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. Mr. Twomey also served as a director and chair of the audit committee of Senomyx, Inc., a flavor technology company, from March 2006 until its sale to Firmenich SA in November 2018. He also served as a director and chair of the audit committee of Cadence Pharmaceuticals, Inc., from July 2006 until it was acquired by Mallinckrodt plc in March 2014. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara.

What is Christopher J. Twomey's net worth?: The estimated net worth of Christopher J. Twomey is at least $142,471.44 as of May 5th, 2022. Mr. Twomey owns 5,112 shares of Tandem Diabetes Care stock worth more than $142,471 as of November 20th. This net worth estimate does not reflect any other assets that Mr. Twomey may own. Learn More about Christopher J. Twomey's net worth.
How do I contact Christopher J. Twomey?: The corporate mailing address for Mr. Twomey and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on Christopher J. Twomey's contact information.
Has Christopher J. Twomey been buying or selling shares of Tandem Diabetes Care?: Christopher J. Twomey has not been actively trading shares of Tandem Diabetes Care over the course of the past ninety days. Learn More on Christopher J. Twomey's trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 2 times. They purchased a total of 5,532 shares worth more than $107,163.68. In the last twelve months, insiders at the medical device company sold shares 1 times. They sold a total of 5,000 shares worth more than $258,400.00. The most recent insider tranaction occured on November, 15th when EVP Mark David Novara bought 532 shares worth more than $12,363.68. Insiders at Tandem Diabetes Care own 2.2% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 11/15/2024.

Christopher J. Twomey Insider Trading History at Tandem Diabetes Care

Christopher J. Twomey Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $27.87

$27.66

$28.60

50 Day Range

MA: $37.19

$27.34

$45.44

2 Week Range

Now: $27.87

$17.33

$53.69

Volume

1,344,288 shs

Average Volume

1,604,687 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36